Canada Research Chair in Pharmacogenomics, Professor Pharmacology and Psychiatry
CAMH and University of Toronto
Rachel Tyndale, PhD, is head of Pharmacogenetics at the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, the Canada Research Chair in Pharmacogenomics, and a Professor in the Departments of Pharmacology & Toxicology, and Psychiatry at the University of Toronto. Dr. Tyndale focuses on sources of variation between individuals in drug response in clinical area of addictions. Dr. Tyndale seeks to identify and understand risk factors, and underlying mechanisms, in substance abuse and to implement genetic approaches to personalize treatment. Her laboratory program also has a major interest in understanding interindividual variation in drug metabolizing enzymes within the brain on effects of drugs and toxins. Dr. Tyndale sits on numerous scientific advisory boards, editorial boards and was chair of steering committee for NIH’s PharmacoGenomics Research Network (PGRN.org). Dr. Tyndale has supervised over 100 scientists, post-doctoral fellows and graduate students, published over 300 papers and book chapters, given over 200 invited presentations and received over 40 awards in both clinical and basic pharmacology. Dr. Tyndale is also a member of numerous journal editorial boards, scientific advisory boards and meeting organizing committees. She is currently serving as a lead writer for the 2018 Surgeon General’s report on Tobacco Cessation.